Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29246043 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL83981 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL254634 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL720143 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL9093899 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL31290858 | 1.00 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Ammonia Solution, Strong SCHEMBL25381565 | 0.97 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Water SCHEMBL9834733 | 0.97 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Water SCHEMBL9674541 | 0.97 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL27412184 | 0.97 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024002284-A1 | FIVE-MEMBERED AND SIX-MEMBERED NITROGEN-CONTAINING COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | 杭州圣域生物医药科技有限公司 | 2024-01-04 | — | — | WO | claimed |
| CN-117304183-A | Five-membered and six-membered nitrogen-containing compound, intermediate thereof, preparation method and application | 杭州圣域生物医药科技有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-116390727-A | N-linked isoquinolinamides as LRRK2 inhibitors, pharmaceutical compositions and uses thereof | 默沙东有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| CN-115942972-A | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2023-04-07 | — | — | CN | claimed |
| CN-113195053-A | Amino acid compounds and methods of use | 普利安特治疗公司 | 2021-07-30 | — | — | CN | claimed |
| WO-2011041713-A2 | PIPERAZINYL ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-04-07 | — | — | WO | claimed |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-04-23 | — | — | US | disclosed |
| US-20260069539-A1 | LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES | POSEIDA THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250382292-A1 | COMPOUNDS FOR TREATING LIGHT CHAIN AMYLOIDOSIS | PROTEGO BIOPHARMA INC (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4652153-A1 | LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES | Poseida Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4592295-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-20250186456-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2025-06-12 | — | — | US | disclosed |
| CN-120109288-A | Electrolyte and lithium ion battery | 宁德国泰华荣新材料有限公司 | 2025-06-06 | — | — | CN | disclosed |
| EP-1658350-A1 | COMPOUNDS FOR USE IN LIQUID CRYSTAL MEDIA | MERCK PATENT GmbH (DE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2006021420-A2 | METHOD FOR THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005019377-A1 | COMPOUNDS FOR USE IN LIQUID CRYSTAL MEDIA | MERCK PATENT GMBH (DE) | 2005-03-03 | — | — | WO | disclosed |
| US-20040218117-A1 | Polarizer, process for preparing the same, optical member and liquid crystal displaying apparatus | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-11-04 | — | — | US | disclosed |
| CN-1521523-A | Polarizer and its manufacturing method ,optical element and liquid crystal display device | ס�ѻ�ѧ��ҵ��ʽ���� | 2004-08-18 | — | — | CN | disclosed |
| US-4448986-A | Preparation of (1R,cis)-oxyimino-substituted cyclopropanecarboxylic acids | SHELL OIL COMPANY (US) | 1984-05-15 | — | — | US | disclosed |
| US-4409398-A | Preparation of (1R, cis)-oxyimino-substituted cyclo-propanecarboxylic acids | SHELL OIL COMPANY (US) | 1983-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069539-A1 | LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES | STARD3, LPCAT3, LPCAT1 | CHRM2 2095/4885CHRM4 2471/4885CHRM5 1761/4885 |
| US-20250186456-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | KRAS, NRAS, TP53 | CHRM2 4872/4885CHRM4 4874/4885CHRM5 4877/4885 |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, HRAS | CHRM2 2762/4885CHRM4 3369/4885CHRM5 4016/4885 |
| US-20250382292-A1 | COMPOUNDS FOR TREATING LIGHT CHAIN AMYLOIDOSIS | TTR, CRYAA, BCL6 | CHRM2 4133/4885CHRM4 4108/4885CHRM5 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.